Get the Stockscreener App
358.33
1.56%
5.51
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $358.33, with a volume of 3.57M.
It is up +1.56% in the last 24 hours and up +6.66% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$352.82
Open:
$354.69
24h Volume:
3.57M
Relative Volume:
1.32
Market Cap:
$193.39B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
24.92
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+6.14%
1M Performance:
+6.66%
6M Performance:
+7.63%
1Y Performance:
+28.38%
1-Day Range:
$354.16
$362.27
1-Week Range:
$337.60
$362.27
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
358.33 | 190.42B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,208.12 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 589.48B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 429.58B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 309.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 295.98B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen updates phase 2 obesity data, shares closely watched by health investors - Ad-hoc-news.de
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles - People.com
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh - TradingView
Amgen Continues To Perform (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen consensus steady ahead of next earnings, shares tracked against big pharma peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (NASDAQ:AMGN) - TradingView
EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked - WSJ
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - marketscreener.com
EMA recommends revoking marketing authorisation for Amgen’s rare-disease drug - WKZO
Amgen faces EU withdrawal of rare-disorder therapy Tavneos - Seeking Alpha
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Amgen highlights obesity pipeline progress, shares track pharma peers - Ad-hoc-news.de
Amgen clears key resistance level, shares range between support and new highs - Ad-hoc-news.de
Price to earnings forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen reports new biosimilar data, shares in focus among healthcare peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (BMV:AMGN) - TradingView
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade - TIKR.com
Amgen raises lower end of 2026 EPS target, shares stay in focus on NASDAQ - Ad-hoc-news.de
Amgen clears new 2026 high, shares extend biotech sector gains - Ad-hoc-news.de
Amgen dividend confirmed and capital plan detailed, shares under steady Wall Street scrutiny - Ad-hoc-news.de
AMGN Faces Market Scrutiny Over Data Integrity Issues - GuruFocus
Inside the FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 - TradingView
Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen (AMGN) - simplywall.st
IgG4-RD: From Diagnostic Delays to Collective Action in Rare Disease Care - Amgen
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Inc. (AMGN) Price Target Raised to $303 After Q1 Model Update - Insider Monkey
Amgen lifts 2026 revenue outlook, shares trade in a tight NASDAQ range - Ad-hoc-news.de
Kyprolis from Amgen Inc.once-weekly regimen reshapes myeloma routine - Ad-hoc-news.de
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story? - The Globe and Mail
(AMGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Update, Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Amgen patent verdict reshapes risk picture, shares hold near recent highs - AD HOC NEWS
Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs Trade Ideas — BCBA:AMGN.CI - TradingView
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
Amgen faces Delaware patent verdict, shares under legal scrutiny - Ad-hoc-news.de
Tezspire from Amgen Inc.severe asthma biologic with shared AstraZeneca launch - AD HOC NEWS
Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN) - Yahoo Finance
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen opens the week with upcoming catalysts, shares on Nasdaq - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
What a Landmark Real-World Study Reveals About Thyroid Eye Disease - Amgen
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):